ResearcherUniversity of MichiganNo recent work listed
Jonathan Maybaum
Matched on ORCID iD 0000-0003-4438-3237; OpenAlex author ID A5046604262; NIH RePORTER profile ID 1868046. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 16
2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 grant · 2016: none · 2017: none · 2018: none · 2019: 1 paper
Papers 5
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… Co-author DOI 10.1200/jco.19.00730↗
- Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-1038↗
- Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Co-author DOI 10.1158/1078-0432.ccr-12-3748↗
- Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Co-author DOI 10.1593/neo.12538↗
- Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Co-author DOI 10.4161/cc.10.24.18661↗
Grants 1
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Theodore Steven Lawrence · 5 shared papers, 1 shared grant, 2011–2019 · strength 0.42
- Grant Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer R01CA138723↗
- Paper Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Pat… DOI 10.1200/jco.19.00730↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Leslie A. Parsels · 5 shared papers, 2011–2019 · strength 0.21
- Paper Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Pat… DOI 10.1200/jco.19.00730↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Paper Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. DOI 10.1593/neo.12538↗
- Meredith Ann Morgan · 5 shared papers, 2011–2019 · strength 0.21
- Paper Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Pat… DOI 10.1200/jco.19.00730↗
- Paper Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. DOI 10.1158/1078-0432.ccr-14-1038↗
- Paper Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. DOI 10.1593/neo.12538↗
- Hari Nathan · 1 shared paper, 2019 · strength 0.08
- Clifford S. Cho · 1 shared paper, 2019 · strength 0.08
- Mark M. Zalupski · 1 shared paper, 2019 · strength 0.08
- Vaibhav Sahai · 1 shared paper, 2019 · strength 0.08
- Kyle Clifford Cuneo · 1 shared paper, 2019 · strength 0.08
- Carl G. Engelke · 2 shared papers, 2013–2014 · strength 0.07
- Dongping Wei · 2 shared papers, 2013–2014 · strength 0.07
- David M. Karnak · 2 shared papers, 2013–2014 · strength 0.07
- Venkatasubbaiah A. Venkatesha · 1 shared paper, 2012 · strength 0.03
- Diane M. Simeone · 1 shared paper, 2012 · strength 0.03
- Qiang Zhang · 1 shared paper, 2013 · strength 0.03
- Sean M. Vance · 1 shared paper, 2011 · strength 0.03
- Erqi Liu Pollom · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.